[바카라 에볼루션 USA] Genexine embarks on a new ‘바카라 에볼루션PROTAC’ journey, ‘dashing back and forth’ with 40+ partnerships

[by Ji, Yong Jun] Genexine has entered the global ‘targeted protein degradation (TPD)’ market through the development of its proprietary 바카라 에볼루션PROTAC platform technology. During the 바카라 에볼루션 USA 2025 conference held in Boston, USA, the company conducted over 40 partnering meetings, underscoring sustained global interest in its pipeline (new drug candidates) currently under development, including the treatment for non-small cell lung cancer (GX-BP1) and atopic dermatitis (GX-BP2).

On June 18 (local time), Genexine CEO Choi Jae-hyun, in an interview with <THE 바카라 에볼루션 during 바카라 에볼루션 USA 2025 in Boston, stated, “We are currently focused on demonstrating the global competitiveness of our differentiated TPD platform and establishing a strategic foothold, while actively pursuing partnership opportunities.”

◇Dashing back and forth for global partnerships

In the first half of this year, Genexine participated in several international 바카라 에볼루션technology conferences, including 바카라 에볼루션 USA, China바카라 에볼루션, 바카라 에볼루션 Korea, and 바카라 에볼루션-Europe, with a primary focus on fostering global partnerships for its 바카라 에볼루션PROTAC platform. Choi emphasized that 바카라 에볼루션PROTAC addresses the limitations of conventional small molecule-based compounds, ‘PROTACs,’ by incorporating a novel structure that directly links a ‘nanobody’ to an ‘E3 ligase.’ Furthermore, the integration of lipid nanoparticle (LNP) delivery technology has dramatically expanded the platform’s capacity for targeted protein degradation.

“Whereas conventional PROTACs are limited to targeting about 7% of intracellular proteins, we are now validating the potential of 바카라 에볼루션PROTAC to address a significantly broader range of targets,” Choi stated. “The global 바카라 에볼루션pharmaceutical companies we engaged with during the 바카라 에볼루션 USA conference expressed considerable interest in this mechanistic differentiation.”

◇Progress status of GX-BP1 and GX-BP2 development

At 바카라 에볼루션 USA, Genexine actively promoted its 바카라 에볼루션PROTAC pipeline, highlighting key development programs. The lead candidates include ‘GX-BP1 (development code),’ a non-small cell lung cancer treatment candidate that targets SOX2 for degradation, and ‘GX-BP2,’ an atopic dermatitis treatment candidate that targets STAT3. GX-BP1 has advanced into preclinical toxicity studies, while GX-BP2 has completed in vivo testing.

Genexine is accelerating the development of GX-BP1, a candidate targeting the ‘SOX2 protein,’ a key transcription factor implicated in squamous cell lung cancer and previously regarded as an undruggable degradation target. In in vivo studies, Genexine confirmed that GX-BP1 successfully induced cellular degradation of SOX2. Choi further explained that subsequent preclinical studies using a lung cancer mouse model demonstrated GX-BP1’s high target selectivity, minimal off-target effects, and significant tumor growth inhibition.

“GX-BP2 yielded more favorable results than the competing drug ‘Dupixent’ in in vivo experiments, and we are internally positioning it as a promising next-generation treatment for autoimmune diseases,” Choi further added.

◇Growing interest in TPD market… “Aiming for early licensing-out”

Choi noted that as data from the pipeline continues to accumulate, market interest has also been increasing. He specifically highlighted that several companies specializing in oncology and dermatology, with whom meetings were held during the 바카라 에볼루션 USA conference, expressed concrete interest and requested follow-up discussions.

In fact, between 2015 and 2024, a total of 87 global TPD-related licensing agreements were concluded, with over 85% of them signed during the ‘platform development or preclinical stages.’ This trend underpins Genexine’s expectation of achieving early-stage technology out-licensing for its 바카라 에볼루션PROTAC platform during the preclinical stage.

“We intend to actively pursue negotiations that may lead to concrete deals, including licensing-out and region- or indication-specific co-development opportunities, centered on GX-BP1 and GX-BP2,” Choi expressed.

◇Prioritizing co-development partnerships

Genexine is also preparing to form co-development partnerships aimed at providing customized target solutions to global pharmaceutical companies. This initiative is supported by the company’s proprietary nanobody library, which enables the tailored designs for specific protein targets.

“Major pharmaceutical companies are approaching us with proposals to collaborate on the design of customized targets of their interest. Once a target is clearly defined, we are capable of generating a candidate within nine months,” Choi said. “This modality is unprecedented, both in Korea and globally. Given the fundamentally different approach, we will actively seek direct collaboration points with global partners,” he further emphasized.